WBR280: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (refreshing WBR questions)
 
(5 intermediate revisions by 2 users not shown)
Line 1: Line 1:
{{WBRQuestion
{{WBRQuestion
|QuestionAuthor=Gerald Chi
|QuestionAuthor=Gerald Chi (Reviewed by Serge Korjian)
|ExamType=USMLE Step 1
|ExamType=USMLE Step 1
|MainCategory=Microbiology, Pharmacology
|MainCategory=Microbiology, Pharmacology
|SubCategory=Head and Neck, Musculoskeletal/Rheumatology
|SubCategory=Head and Neck, Hematology, Musculoskeletal/Rheumatology
|MainCategory=Microbiology, Pharmacology
|MainCategory=Microbiology, Pharmacology
|SubCategory=Head and Neck, Musculoskeletal/Rheumatology
|SubCategory=Head and Neck, Hematology, Musculoskeletal/Rheumatology
|MainCategory=Microbiology, Pharmacology
|MainCategory=Microbiology, Pharmacology
|SubCategory=Head and Neck, Musculoskeletal/Rheumatology
|SubCategory=Head and Neck, Hematology, Musculoskeletal/Rheumatology
|MainCategory=Microbiology, Pharmacology
|MainCategory=Microbiology, Pharmacology
|MainCategory=Microbiology, Pharmacology
|MainCategory=Microbiology, Pharmacology
|MainCategory=Microbiology, Pharmacology
|MainCategory=Microbiology, Pharmacology
|SubCategory=Head and Neck, Musculoskeletal/Rheumatology
|SubCategory=Head and Neck, Hematology, Musculoskeletal/Rheumatology
|MainCategory=Microbiology, Pharmacology
|MainCategory=Microbiology, Pharmacology
|SubCategory=Head and Neck, Musculoskeletal/Rheumatology
|SubCategory=Head and Neck, Hematology, Musculoskeletal/Rheumatology
|MainCategory=Microbiology, Pharmacology
|MainCategory=Microbiology, Pharmacology
|SubCategory=Head and Neck, Musculoskeletal/Rheumatology
|SubCategory=Head and Neck, Hematology, Musculoskeletal/Rheumatology
|MainCategory=Microbiology, Pharmacology
|MainCategory=Microbiology, Pharmacology
|SubCategory=Head and Neck, Musculoskeletal/Rheumatology
|SubCategory=Head and Neck, Hematology, Musculoskeletal/Rheumatology
|MainCategory=Microbiology, Pharmacology
|MainCategory=Microbiology, Pharmacology
|SubCategory=Head and Neck, Hematology, Musculoskeletal/Rheumatology
|MainCategory=Microbiology, Pharmacology
|MainCategory=Microbiology, Pharmacology
|SubCategory=Head and Neck, Musculoskeletal/Rheumatology
|MainCategory=Microbiology, Pharmacology
|Prompt=An 8-year-old girl with a history of thalassaemia major presents to the emergency department with low-grade fever, leg pain, and malaise for the past week. Her blood pressure is 110/60 mm Hg, heart rate is 90/min, and temperature is 37.8 ᵒC (98 ᵒF). On physical examination, tibia is red, swollen, and tender to palpation. Two sets of blood culture are positive for a gram-negative bacteria and the diagnosis of osteomyelitis is made. If the physician decides to start her on antibiotics, which of the following drugs should be used in this case?
|SubCategory=Head and Neck, Hematology, Musculoskeletal/Rheumatology
|Explanation=Patients with a history of hemoglobinopathy such as sickle cell disease and thalassemia are prone to have osteomyelitis secondary to Salmonella infection. Other risk factors include transfusions and iron chelation therapies.
|Prompt=An 8-year-old girl with a history of thalassaemia major presents to the emergency department with low-grade fever, leg pain, and malaise for the past week. Her blood pressure is 110/60 mm Hg, heart rate is 90/min, and temperature is 37.8 ᵒC (100 ᵒF). On physical examination, her anterior left shin is red, swollen, and tender to palpation. Following an extensive work-up, the diagnosis of tibial osteomyelitis is confirmed. Cultures from bone biopsies reveal gram-negative rods. Which of the following regimens is the most appropriate for the initial management of this patient?
|AnswerA=Intravenous ciprofloxacin
|Explanation=Beta-thalassemia major is and inherited autosomal-recessive blood disorder characterized by reduced or absent synthesis of beta hemoglobin chains resulting in severe anemia requiring transfusions, splenomegaly, and bone deformities due to marrow expansion. Beta-thalassemia major, and other hemoglobinopathies such as sickle cell disease, predispose patients to osteomyelitis secondary to ''Salmonella'' species. Among these patients, ''Salmonella'' osteomyelitis is more commonly observed than in the general population; however, ''S. aureus'' remains the predominant cause of osteomyelitis. Several hypotheses have been proposed to explain the higher incidence of ''Salmonella'' osteomyelitis in hemoglobinopathies. Given the impairment in effective oxygen delivery in these disorders, some have suggested that patchy ischemic infarction of the bowels may occur allowing transient mucosal barrier breakdown and passage of the bacteria into the bloodstream. Empiric treatment of hematogenous osteomyelitis in patients with hemoglobinopathies includes coverage for ''Salmonella'', ''E. coli'', and ''S. aureus'' species. Regimens should include [[ciprofloxacin]] and either [[oxacillin]]/[[nafcillin]]/[[ceftriaxone]] or [[vancomycin]]/[[linezolid]], depending on risk of MRSA. In patients with bone biopsy diagnosis of ''Salmonella'' osteomyelitis, treatment with ciprofloxacin is recommended if susceptibility is documented.
|AnswerAExp=Correct - Intravenous ciprofloxacin is the drug of choice for Salmonella osteomyelitis.
|AnswerA=Ciprofloxacin
|AnswerB=Intravenous linezolid
|AnswerAExp=Empiric treatment of hematogenous osteomyelitis in patients with hemoglobinopathies includes coverage for Salmonella, ''E. coli'', and ''S. aureus'' species. Regimens should include ciprofloxacin and either oxacillin/nafcillin/ceftriaxone or vancomycin/linezolid depending on risk of MRSA.
|AnswerBExp=Incorrect - Intravenous linezolid may be used as an alternative regimen for MRSA osteomyelitis.
|AnswerB=Linezolid
|AnswerC=Intravenous nafcillin
|AnswerBExp=Although linezolid provides adequate coverage for staphylococcal species, it does not cover ''Salmonella'' species, which are highly likely in this case given the history of thalassemia and the culture results.
|AnswerCExp=Incorrect - Intravenous nafcillin may be used as a primary regimen for S. aureus osteomyelitis.
|AnswerC=Ampicillin
|AnswerD=Intravenous vancomycin
|AnswerCExp=Although ampicillin provides adequate coverage for staphylococcal species, it does not cover ''Salmonella'' species, which are highly likely in this case given the history of thalassemia and the culture results.
|AnswerDExp=Incorrect - Intravenous vancomycin may be used as an alternative regimen for S. aureus osteomyelitis.
|AnswerD=Vancomycin
|AnswerE=Intravenous cefazolin
|AnswerDExp=Although vancomycin provides adequate coverage for staphylococcal species, it does not cover ''Salmonella'' species, which are highly likely in this case given the history of thalassemia and the culture results.
|AnswerEExp=Incorrect - Intravenous cefazolin may be used as a primary regimen for S. aureus osteomyelitis.
|AnswerE=Clindamycin
|AnswerEExp=Although clindamycin provides adequate coverage for staphylococcal species, it does not cover ''Salmonella'' species, which are highly likely in this case given the history of thalassemia and the culture results.
|EducationalObjectives=Empiric treatment of hematogenous osteomyelitis in patients with hemoglobinopathies includes coverage for Salmonella, ''E. coli'', and ''S. aureus'' species. Regimens should include ciprofloxacin and either oxacillin/nafcillin/ceftriaxone or vancomycin/linezolid depending on risk of MRSA.
|References=Burnett MW, Bass JW, Cook BA. Etiology of osteomyelitis complicating sickle cell disease. Pediatrics. 1998;101(2):296-7.
|RightAnswer=A
|RightAnswer=A
|WBRKeyword=Salmonella
|WBRKeyword=Salmonella, Osteomyelitis, Antibiotics, Thalassemia, Sickle cell disease
|Approved=No
|Approved=Yes
}}
}}

Latest revision as of 02:59, 28 October 2020

 
Author PageAuthor::Gerald Chi (Reviewed by Serge Korjian)
Exam Type ExamType::USMLE Step 1
Main Category MainCategory::Microbiology, MainCategory::Pharmacology
Sub Category SubCategory::Head and Neck, SubCategory::Hematology, SubCategory::Musculoskeletal/Rheumatology
Prompt [[Prompt::An 8-year-old girl with a history of thalassaemia major presents to the emergency department with low-grade fever, leg pain, and malaise for the past week. Her blood pressure is 110/60 mm Hg, heart rate is 90/min, and temperature is 37.8 ᵒC (100 ᵒF). On physical examination, her anterior left shin is red, swollen, and tender to palpation. Following an extensive work-up, the diagnosis of tibial osteomyelitis is confirmed. Cultures from bone biopsies reveal gram-negative rods. Which of the following regimens is the most appropriate for the initial management of this patient?]]
Answer A AnswerA::Ciprofloxacin
Answer A Explanation [[AnswerAExp::Empiric treatment of hematogenous osteomyelitis in patients with hemoglobinopathies includes coverage for Salmonella, E. coli, and S. aureus species. Regimens should include ciprofloxacin and either oxacillin/nafcillin/ceftriaxone or vancomycin/linezolid depending on risk of MRSA.]]
Answer B AnswerB::Linezolid
Answer B Explanation AnswerBExp::Although linezolid provides adequate coverage for staphylococcal species, it does not cover ''Salmonella'' species, which are highly likely in this case given the history of thalassemia and the culture results.
Answer C AnswerC::Ampicillin
Answer C Explanation AnswerCExp::Although ampicillin provides adequate coverage for staphylococcal species, it does not cover ''Salmonella'' species, which are highly likely in this case given the history of thalassemia and the culture results.
Answer D AnswerD::Vancomycin
Answer D Explanation AnswerDExp::Although vancomycin provides adequate coverage for staphylococcal species, it does not cover ''Salmonella'' species, which are highly likely in this case given the history of thalassemia and the culture results.
Answer E AnswerE::Clindamycin
Answer E Explanation AnswerEExp::Although clindamycin provides adequate coverage for staphylococcal species, it does not cover ''Salmonella'' species, which are highly likely in this case given the history of thalassemia and the culture results.
Right Answer RightAnswer::A
Explanation [[Explanation::Beta-thalassemia major is and inherited autosomal-recessive blood disorder characterized by reduced or absent synthesis of beta hemoglobin chains resulting in severe anemia requiring transfusions, splenomegaly, and bone deformities due to marrow expansion. Beta-thalassemia major, and other hemoglobinopathies such as sickle cell disease, predispose patients to osteomyelitis secondary to Salmonella species. Among these patients, Salmonella osteomyelitis is more commonly observed than in the general population; however, S. aureus remains the predominant cause of osteomyelitis. Several hypotheses have been proposed to explain the higher incidence of Salmonella osteomyelitis in hemoglobinopathies. Given the impairment in effective oxygen delivery in these disorders, some have suggested that patchy ischemic infarction of the bowels may occur allowing transient mucosal barrier breakdown and passage of the bacteria into the bloodstream. Empiric treatment of hematogenous osteomyelitis in patients with hemoglobinopathies includes coverage for Salmonella, E. coli, and S. aureus species. Regimens should include ciprofloxacin and either oxacillin/nafcillin/ceftriaxone or vancomycin/linezolid, depending on risk of MRSA. In patients with bone biopsy diagnosis of Salmonella osteomyelitis, treatment with ciprofloxacin is recommended if susceptibility is documented.

Educational Objective: Empiric treatment of hematogenous osteomyelitis in patients with hemoglobinopathies includes coverage for Salmonella, E. coli, and S. aureus species. Regimens should include ciprofloxacin and either oxacillin/nafcillin/ceftriaxone or vancomycin/linezolid depending on risk of MRSA.
References: Burnett MW, Bass JW, Cook BA. Etiology of osteomyelitis complicating sickle cell disease. Pediatrics. 1998;101(2):296-7.]]

Approved Approved::Yes
Keyword WBRKeyword::Salmonella, WBRKeyword::Osteomyelitis, WBRKeyword::Antibiotics, WBRKeyword::Thalassemia, WBRKeyword::Sickle cell disease
Linked Question Linked::
Order in Linked Questions LinkedOrder::